596302 Disclosed herein are compounds of the formula I, wherein the variables are defined in the specification, and their use in the treatment of a disorder or a disease in a subject mediated by aldosterone synthase, such as hypokalemia, hypertension, Conn&rsquo；s disease, renal failure, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, cerebrovascular diseases, vascular diseases, retinopathy. neuropathy, insulinopathy, edema, endothelial dysfunction, baroreceptor dysfunction, migraine headaches, heart failure such as congestive heart failure, arrhythmia, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, impaired diastolic filling, systolic dysfunction. ischemia, hypertrophic cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, decreased ejection fraction, cardiac lesions, vascular wall hypertrophy, endothelial thickening and fibrinoid necrosis of coronary arteries. Exemplary embodiments of the compound include the following: N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)ethanesulfonamide； N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yI)-2,2,2-trifluoroethanesulfonamide； cyclopropanesulfonic acid[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yI]-amide； (R)-N-((5-(4-cyano-3-fluorophenyl)pyridine-3-yl)(cyclopropyl)methyl) ethanesulfonamide； and N-(cyclopropyl(5-benzo[b]thiophen-2-yl-pyridin-3-yl)methyl)ethanesulfonamide；
